











































Common, low-frequency, rare, and ultra-rare coding variants
contribute to COVID-19 severity
Citation for published version:
WES/WGS Working Group Within the HGI 2021, 'Common, low-frequency, rare, and ultra-rare coding
variants contribute to COVID-19 severity', Human Genetics. https://doi.org/10.1007/s00439-021-02397-7
Digital Object Identifier (DOI):
10.1007/s00439-021-02397-7
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:




This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use,
sharing, adaptation, distribution and reproduction in any medium or format, as long
as you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes
were made. T
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.





Common, low‑frequency, rare, and ultra‑rare coding variants 
contribute to COVID‑19 severity
Chiara Fallerini1,2 · Nicola Picchiotti3,4 · Margherita Baldassarri1,2 · Kristina Zguro1 · Sergio Daga1,2 · 
Francesca Fava1,2,5 · Elisa Benetti1 · Sara Amitrano5 · Mirella Bruttini1,2,5 · Maria Palmieri1,2 · Susanna Croci1,2 · 
Mirjam Lista1,2 · Giada Beligni1,2 · Floriana Valentino1,2 · Ilaria Meloni1,2 · Marco Tanfoni3 · Francesca Minnai6 · 
Francesca Colombo6 · Enrico Cabri7 · Maddalena Fratelli7 · Chiara Gabbi8 · Stefania Mantovani9 · Elisa Frullanti1,2 · 
Marco Gori3,10 · Francis P. Crawley11 · Guillaume Butler‑Laporte12,13 · Brent Richards12,14,15 · Hugo Zeberg16 · 
Miklos Lipcsey17,18 · Michael Hultström17,19 · Kerstin U. Ludwig20 · Eva C. Schulte21,22,23 · Erola Pairo‑Castineira24,25 · 
John Kenneth Baillie24,25,26 · Axel Schmidt20 · Robert Frithiof17 · WES/WGS Working Group Within the HGI · 
GenOMICC Consortium · GEN‑COVID Multicenter Study · Francesca Mari1,2,5 · Alessandra Renieri1,2,5,27  · 
Simone Furini1
Received: 14 September 2021 / Accepted: 26 October 2021 
© The Author(s) 2021
Abstract
The combined impact of common and rare exonic variants in COVID-19 host genetics is currently insufficiently understood. 
Here, common and rare variants from whole-exome sequencing data of about 4000 SARS-CoV-2-positive individuals were 
used to define an interpretable machine-learning model for predicting COVID-19 severity. First, variants were converted 
into separate sets of Boolean features, depending on the absence or the presence of variants in each gene. An ensemble of 
LASSO logistic regression models was used to identify the most informative Boolean features with respect to the genetic 
bases of severity. The Boolean features selected by these logistic models were combined into an Integrated PolyGenic 
Score that offers a synthetic and interpretable index for describing the contribution of host genetics in COVID-19 severity, 
as demonstrated through testing in several independent cohorts. Selected features belong to ultra-rare, rare, low-frequency, 
and common variants, including those in linkage disequilibrium with known GWAS loci. Noteworthily, around one quarter 
of the selected genes are sex-specific. Pathway analysis of the selected genes associated with COVID-19 severity reflected 
the multi-organ nature of the disease. The proposed model might provide useful information for developing diagnostics and 
therapeutics, while also being able to guide bedside disease management.
Introduction
For almost 2 years, COVID-19 has demonstrated itself to be 
a disease having a broad spectrum of clinical presentations: 
from asymptomatic patients to those with severe symptoms 
leading to death or persistent disease (“long COVID”) (Liv-
ingston and Bucher 2020; Chen et al. 2019; Zhang et al. 
2020a). While developing vaccination programmes and 
other preventive measures to significantly dampen infection 
transmission and reduce disease expression, a much deeper 
and more precise understanding of the interplay between 
SARS-CoV-2 and host genetics is required to support the 
development of treatments for new virus variants as they 
arise. Furthermore, advances in modelling the interplay 
between SARS-CoV-2 and host genetics hold significant 
promise for addressing other complex diseases. In this study, 
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we demonstrate the value of genetic modelling with its direct 
translatability into drug development and clinical care in the 
context of a severe public health crisis.
The identification of host genetic factors modifying dis-
ease susceptibility and/or disease severity has the potential 
to reveal the biological basis of disease susceptibility and 
outcome as well as to subsequently contribute to treatment 
amelioration (Elhabyan et al. 2020). From a scientific point 
of view, COVID-19 represents a particularly interesting 
and accessible complex disorder for modeling host genetic 
data because the environmental factor (SARS-CoV-2) can 
be readily identified by a PCR-based swab test. The still 
moderate viral genome variability has thus far been shown 
to have relatively low impact on disease severity (Islam et al. 
2020) where currently age, sex, and comorbidities are the 
major factors predicting disease susceptibility and outcome 
(Li et al. 2021). While these factors certainly have significant 
value for prediction, they provide limited insights into dis-
ease pathophysiology and are of limited relevance for drug 
development.
Common variants in the human genome affecting the 
susceptibility to SARS-CoV-2 infections and COVID-19 
severity have been successfully identified by Genome-Wide 
Association Studies (GWASs) (Severe Covid-19 GWAS 
Group (2020); Pairo-Castineira et  al. 2020; COVID-19 
Host Genetics Initiative et al. 2021). However, these vari-
ants only explain a small fraction of trait variability and, 
as it is well documented, GWASs are difficult to interpret 
because they often associate non-coding variants with phe-
notype; therefore, the relevant genes need to be pinpointed 
by deeper follow-up analyses. In contrast, next-generation 
sequencing-based studies have identified variants in a few 
genes-related to innate immunity which can solely under-
lie rare severe forms of COVID-19 (Zhang et al. 2020b; 
Van der Made et al. 2020; Fallerini et al. 2021a; Solanich 
et al. 2021). In these rare affected families, the predictivity 
is high as the susceptibility for severe COVID-19 follows 
Mendelian inheritance patterns. However, these patients rep-
resent only a small proportion of those severely affected by 
COVID-19. Taken together, genetic findings can currently 
only explain a limited proportion of COVID-19 susceptibil-
ity and severity, in spite of the relatively high predicted her-
itability of COVID-19 and COVID-19 symptoms (Williams 
et al. 2020). A better and more holistic understanding of host 
genetics could support the development of more specific, or 
even targeted drugs and treatment interventions leading to 
less morbidity and mortality.
The Italian GEN-COVID Multicenter Study collected 
more than 2000 biospecimens and clinical data from SARS-
CoV-2-positive individuals (Daga et al. 2021), and whole-
exome sequencing (WES) analysis contributed to the identi-
fication of rare variants (Fallerini et al. 2021a) and common 
polymorphisms (Baldassarri et al. 2021a; Croci et al. 2021; 
Fallerini et al. 2021b) associated with COVID-19 severity. 
In 2020, we started to investigate how common variants may 
combine with rare variants to determine COVID-19 sever-
ity in WES data using a first small cohort of hospitalized 
patients. This pilot analysis revealed that the combination 
of rare and common variants could potentially impact clini-
cal outcome (Benetti et al. 2020a). We then proposed a new 
post-Mendelian model for a genetic characterization of the 
disorder (Picchiotti et al. 2021) based on an adapted Poly-
genic Risk Score (PRS) (Mars et al. 2020), called Integrated 
PolyGenic Score (IPGS). This allowed us to reach a more 
precise disease severity prediction than that based on sex and 
age alone. In this article, we substantially improve this post-
Mendelian model to include ultra-rare and low-frequency 
variants while also demonstrating that IPGS significantly 
contributes to predictivity in combination with—as well as 
alongside—age and sex, and is able to extract patient-spe-
cific genes. The IPGS predictivity was also sustained in three 
independent European cohorts of the WES/Whole-Genome 
Sequencing study working group within the COVID-19 




Five different cohorts (from Germany, Italy, Quebec, Swe-
den, UK) contributed to this study as described in Supple-
mentary Table 1. For multi ancestry cohorts (Quebec and 
UK), the subpopulation of European Ancestry was included 
in the study. Institutional Review Board approval was 
obtained for each study (Supplementary Table 1).
Phenotype definitions
The training of the model proposed for predicting the sever-
ity of COVID-19 requires as inputs the exome variants, age, 
sex, and COVID-19 severity assessed using a modified ver-
sion of the WHO COVID-19 Outcome Scale (COVID-19 
Therapeutic Trial Synopsis 2020) as coded into the follow-
ing six classifications: (1) death; (2) hospitalized receiving 
invasive mechanical ventilation; (3) hospitalized, receiving 
continuous positive airway pressure (CPAP) or bilevel posi-
tive airway pressure (BiPAP) ventilation; (4) hospitalized, 
receiving low-flow supplemental oxygen; (5) hospitalized, 
not receiving supplemental oxygen; and (6) not hospitalized. 
The aim of the model is to predict a binary classification 
of patients into mild and severe cases, where a patient is 
considered severe if hospitalized and receiving any form 
of respiratory support (WHO severity-grading equal to 4 or 
higher in 8 points classification). The next section describes 
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how the annotation of exome variants and the selection of 
patients were performed in the GEN-COVID cohort. Follow-
ing this, the training and testing of the model are described.
Massive parallel sequencing
GEN‑COVID cohort
Whole-exome sequencing with at least 97% coverage at 
20x was performed using the Illumina NovaSeq6000 Sys-
tem (Illumina, San Diego, CA, USA). Library preparation 
was performed using the Illumina Exome Panel (Illumina) 
according to the manufacturer's protocol. Library enrich-
ment was tested by qPCR, and the size distribution and 
concentration were determined using Agilent Bioanalyzer 
2100 (Agilent Technologies, Santa Clara, CA, USA). The 
Novaseq6000 System (Illumina) was used for DNA sequenc-
ing through 150 bp paired-end reads. Variant calling was 
performed according to the GATK4 (O’Connor and Auwera 
2020) best practice guidelines, using BWA (Li and Durbin 
2010) for mapping and ANNOVAR (Wang et al. 2010) for 
annotating.
Swedish cohort
Whole-exome sequencing was performed using the Twist 
Bioscience exome capture probe and was sequenced on the 
Illumina NovaSeq6000 platform. Data were then analyzed 
using the McGill Genome Center bioinformatics pipeline 
(https:// doi. org/ 10. 1093/ gigas cience/ giz037) in accordance 
with GATK best practices.
DeCOI Germany
800–1000 ng of genomic DNA of each individual was frag-
mented to an average length of 350 bp. Library preparation 
was performed using the TruSeq DNA PCR-free kit (Illu-
mina, San Diego, CA, USA) according to the manufacturer’s 
protocol. Whole-genome sequences were obtained as 150 bp 
paired-end reads on S4 flow cells using the NovaSeq6000 
system (Illumina). The intended average sequencing depth 
was 30X. The DRAGEN pipeline (Illumina, version 3.6.3 
or 3.5.7) was used for alignment and joint variant calling 
was performed with the Glnexus software (version 1.3.2). 
Individuals with a 20-fold coverage in less than 96% of the 
protein-coding sequence were removed as well as related 
individuals to retain only from related pairs. Variant QC was 
performed using hail (version 0.2.58). European individuals 
were selected by performing PCA analysis along with the 
1000 genomes data. Finally, annotation was performed using 
Variant Effect Predictor (VEP, version 101). In the present 
study, only individuals from the BoSCO and CoMRI sub-
studies were included.
BQC‑19
Whole-genome sequencing at mean coverage of 30x was 
performed on the Illumina NovaSeq6000 platform, then 
analyzed using the McGill Genome Center bioinformatics 
pipeline (https:// doi. org/ 10. 1093/ gigas cience/ giz037), in 
accordance with GATK best practice guidelines.
GenOMICC/ISARIC4C
Whole-genome sequencing at mean coverage of 20x was 
performed on the Illumina NovaSeq6000 platform and 
then analyzed using the DRAGEN pipeline (software 
v01.011.269.3.2.22 , hardware v01.011.269). Variants were 
genotyped with the GATK GenotypeGVCFs tool v4.1.8.1.
PC analysis
The genetic ancestry of the patients was estimated using 
a random forest classifier. SNPs of autosomes with MAF 
above 10% and in linkage disequilibrium were extracted 
from the 1000 genome project using BCFTOOLS (Danecek 
et al. 2021), and intersected with variants from the GEN-
COVID cohort. The resulting set of variants was used to 
compute 6 Principal Components by PLINK (Purcell et al. 
2007) using samples from the 1000 genome projects. GEN-
COVID samples were projected along the same Principal 
Components. The Random Forest classifier, as implemented 
in the R library randomForest (Liaw and Wiener 2002), was 
trained using samples from 1000 genomes with known 
ancestry, and then used to predict ancestry for the GEN-
COVID cohort. To avoid bias in the analysis due to the dif-
ferent ethnicity, only patients of genetic European ancestry 
were retained for further analyses.
Definition of the Boolean features
Variants were converted into 12 sets of Boolean features to 
better represent the variability at the gene-level. First, any 
variant not impacting on the protein sequence was discarded. 
Then, the remaining variants were classified according to 
their minor allele frequency (MAF) as reported in gnomAD 
for the reference population as: ultra-rare, MAF < 0.1%; 
rare, 0.1% ≤ MAF < 1%; low-frequency, 1% ≤ MAF < 5%; 
and common, MAF ≥ 5%. Non-Finnish European (NFE) 
was used as a reference population. SNPs with MAF not 
available in gnomAD were treated as ultra-rare. INDELs 
with frequency not available in gnomAD were treated as 
ultra-rare when present only once in the cohort and oth-
erwise discarded as possible artefacts of sequencing. For 
the ultra-rare variants, 3 alternative Boolean representations 
were defined, which are designed to capture the autosomal 
dominant (AD), autosomal recessive (AR), and X-linked 
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(XL) model of inheritance, respectively. The AD and AR 
representations included a feature for all the genes on auto-
somes. These features were equal to 1 when the correspond-
ing gene presented at least 1 for the AD model, or 2 for the 
AR model, variants in the ultra-rare frequency range and 
0 otherwise. The XL representation included only genes 
belonging to the X chromosome. These features were equal 
to 1 when the corresponding gene presented at least 1 vari-
ant in the ultra-rare frequency range and 0 otherwise. The 
same approach was used to define AD, AR, and XL Boolean 
features for the rare and low-frequency variants. Common 
variants were represented using a different approach that 
is designed to better capture the presence of alternative 
haplotypes. For each gene, all the possible combinations 
of common variants were computed. For instance, in the 
case of a gene belonging to an autosome with 2 common 
variants (named A and B), 3 combinations are possible (A, 
B, and AB), and (consequently) 3 Boolean features were 
defined both for the AD and AR model. In the AR model 
each of these 3 features was equal to 1 if all the variants in 
that particular combination were present in the homozygous 
state and 0 otherwise. The same rule was used for the AD 
model, but setting the feature to 1 even if the variants in 
that particular combination are in the heterozygous state. In 
both models, AD and AR, a further feature was defined for 
each gene to represent the absence of any of the previously 
defined combinations. In the AD model, this feature was 
equal to 1 if no common variant is present and 0 otherwise; 
in the AR model, it is equal to 1 if no common variant is 
present in the homozygous state and 0 otherwise. The same 
approach was used to define the set of Boolean features for 
common variants in genes belonging to the X chromosome. 
The full list of Boolean representations is reported in Sup-
plementary Table 2.
Connectome analysis
To measure the relatedness of the genes in our list with 
known genes related to viral susceptibility and disease sever-
ity, we used the human gene connectome (HGC—http:// hgc. 
rocke feller. edu/). To define the lists of core genes we used 
three different steps. To probe the initial processes of virus 
entry and intracellular replication, we used genes coding 
for the virus–human proteins interactome found by Gordon 
et al. (2020) and we added a small set of genes known to 
be important for virus entry (https:// viral zone. expasy. org/ 
9077). To extend the study to the whole host response to 
the viral infection, we used the PanelApp https:// panel app. 
genom icsen gland. co. uk). Finally, we used the union of 
GWAS loci (Severe Covid-19 GWAS Group (2020; Pairo-
Castineira et al. 2020; COVID-19 Host Genetics Initiative 
et al. (2021)) and the genes in eQTL with them (by GTEX 
analysis), the genes already demonstrated to be associated 
with severity in functional studies and the list deduced from 
integrative genomic analyses by Pathak et al. (2021).
Model training
The dataset was divided into a training set and a testing 
set (90/10), and the entire procedure described in this sec-
tion was performed using only samples in the training set. 
A bootstrap approach with 100 iterations was adopted to 
train the model. At each bootstrap iteration, 90% of the 
samples were selected (without replication), and the fol-
lowing two steps were performed: (step 1) selection of the 
most relevant features for each Boolean representations; 
and (step 2) definition of the weights of the Integrated 
Polygenic Score (IPGS). After the 100 bootstrap itera-
tions, the information extracted on relevant features and 
weighting factors are merged to define the final IPGS (step 
3). The IPGS is then used, together with age and sex, for 
training a model that predicts the COVID-19 severity (step 
4). These four steps of the training procedure are described 
in detail in the next subsections. Since the model is based 
on a combination of rare and common variants, the train-
ing procedure should be performed using a dataset with 
homogeneous ancestry.
Step 1: Features’ selection
The subsets of the most relevant features were identified 
using logistic regression models with least absolute shrink-
age and selection operator (LASSO) regularization. Sepa-
rate logistic models were trained for each of the 12 sets of 
Boolean features. The predicted outcome variable for each 
of these models was a re-classified phenotype adjusted by 
age and sex. To compute these re-classified phenotypes as 
adjusted by age and sex, the patients were first divided into 
males and females. Then, for each sex, an ordinal logistic 
regression model was fitted using the age to predict the 
WHO phenotype classification into six grades. The ordi-
nal logistic regression model was chosen as: it imposes a 
simple monotone relation between input feature and target 
variable; and it provides easily interpretable thresholds 
between the predicted classes. The patients with a predicted 
grading equal to the actual grading were excluded. The 
remaining patients were divided into two classes depend-
ing on whether their actual phenotype was milder or more 
severe than the one expected for a patient of that age and sex. 
This procedure has the benefit of isolating patients whose 
genetic factors are most important for predicting COVID-19 
severity. This binary trait, i.e. phenotype more/less severe 
than expected, was used as the outcome variable for the 12 
LASSO logistic models based on the 12 separate Boolean 
representations. For each LASSO model, the regularization 
strength was optimized by tenfold cross-validation with 50 
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equally spaced values in the logarithmic scale in the range 
 [10− 2,  101]. The optimal regularization strength was selected 
as the one with the best trade-off between the simplicity of 
the model and the cross-validation score, i.e. as the highest 
regularization strength providing an average score closer 
to the highest average score than 0.5 standard deviations. 
Once the regularization strength was defined, the LASSO 
model was re-trained using all the samples in that particular 
bootstrap iteration. The features with non-null coefficients 
are the ones selected for the next step. In summary, for each 
bootstrap iteration, this procedure returns 12 lists of features 
(one for each Boolean representation) that are expected to 
be the most important features for predicting the pheno-
type adjusted by age and sex (in that particular bootstrap 
iteration).
Step 2: Weights of the Integrated Polygenic Score (IPGS)
In the previous step, the Boolean representations are con-
sidered isolated from each other. The aim of the IPGS is to 
combine information from different representations (Eq. 1). 
To reach this goal, it is necessary to compute the relative 
weights of the different contributions. For each bootstrap 
iteration, the list of relevant features extracted as described 
in the previous section are used to compute the number of 
features that are associated with mildness or severity for the 
different frequency ranges. For instance, n corresponds to 
the number of features associated with r the mild pheno-
type coming from Boolean features computed for variants 
in the frequency range [0.1%, 1%]. A feature is considered 
associated with the mild phenotype when its coefficient 
in the LASSO model estimated in step 1 is negative, i.e. 
it contributes to the prediction of the phenotype adjusted 
by age and sex in the direction of a phenotype less severe 
than what expected at that particular age and sex. The same 
rule, applied to the corresponding Boolean representation, 
is used to define the other feature-counts appearing in Eq. 
(1). The weighting factors in Eq. (1) were estimated as the 
ones that maximize the Silhouette coefficient of the separa-
tion between the clusters of patients more/less severe than 
expected. The minimization was performed with weighting 
factors restricted to the following ranges: FLF ∈ [1, 4], FR ∈ 
[2, 8], and FUR ∈ [5, 100].
This procedure returns three optimal values for the weigh-
ing factors associated with each bootstrap iteration.
Step 3: IPGS definition
In this step, the data extracted at each bootstrap iteration 
in steps 1 and 2 are combined to define the IPGS. First, for 
each of the Boolean features, of all the 12 representations, 
the number of times this feature was selected in the 100 
bootstrap iterations is computed. Then, the entire bootstrap 
procedure is repeated using random input phenotypes, and 
the 5th percentile of the number of times that a feature is 
associated with a random phenotype is estimated. This 
threshold, computed separately for each Boolean representa-
tion, was used to select which Boolean features are included 
in the final model. As no significant association is expected 
among the Boolean features and the random phenotype, the 
threshold of the 5th percentile is expected to exclude with 
a 95% level of confidence the possible false positive asso-
ciations. For the GEN-COVID cohort, the features selected 
correspond to ~ 4.4% of the initial number of Boolean fea-
tures. The weighing factors in Eq. (1) were computed as the 
median values of the estimates obtained in the 100 bootstrap 
iterations.
Step 4: Training of the predictive model based on age, sex, 
and IPGS
The procedure described in the previous sections completely 
defines how to calculate the IPGS. The predictive model of 
the binary COVID-19 severity (hospitalized patients with 
any form of respiratory support versus all other patients) 
was defined as a logistic model that uses as input features 
IPGS, age, and sex. It should be noted that in steps 1-3, 
only patients that deviates from their expected severity based 
on age and sex were used. The procedure was designed to 
isolate the genetic basis of COVID-19 severity. Instead, in 
this final step, IPGS, age and sex are combined to predict 
the actual COVID-19 severity, i.e. hospitalized patients with 
any form of respiratory support. To prevent overfitting, the 
model was fitted using 466 samples different from the train-
ing set adopted in steps 1–3. During the fitting procedure, 
the class unbalancing is tackled by penalizing the misclas-
sification of the minority class with a multiplicative factor 
inversely proportional to the class frequencies. The percen-
tile normalization of the IPGS scores is performed within 
each cohort. An alternative logistic model that used as input 
features only age and sex was also fitted on the same training 
set. The comparison between the two models is intended to 
evaluate if the genetic information summarized in the IPGS 
improves the prediction of severity compared to a model 
based on age and sex alone. A further logistic regression 
model is fitted by only considering the IPGS variable.
Model testing
The training procedure returned 2 logistic models to be com-
pared: one using as input features only age and sex, and the 
other one using as input features age, sex, and the IPGS. 
These models were tested, without any further adjustment, 
using other cohorts of European ancestry. The performances 
of the two models, with and without IPGS, were evaluated 
and compared in terms of accuracy, precision, sensitivity, 
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and specificity. The increases of the performances are evalu-
ated with respect to the performances of a model where the 
values of the IPGS feature have been shuffled, by computing 
the p value on the empirical null distribution. In addition, the 
empirical probability density function of IPGS has been esti-
mated for the severe and non-severe patients of the cohort 
including both train and test sets and a t test is carried out 
to evaluate whether the means of the two distributions were 
significantly different. As a further evaluation of the impor-
tance of the IPGS score on the severity prediction, univariate 
logistic regression models using as independent variables 
age (continuous represented in decades), sex, and IPGS were 
fitted to the dataset that combines both the training set and 
the testing sets for a total of 2240 patients. These models 
were used to estimate the odds ratios and the p values of the 
association with the severe phenotype. Furthermore, a mul-
tivariable logistic regression was fitted using IPGS, age, and 
sex together. Finally, a multivariable logistic regression was 
performed using as predictor variables: IPGS, age, sex and 
comorbidities (congestive/ischemic heart failure; asthma/
COPD/OSAS; diabetes; hypertension; cancer). This latter 
model has been fitted in the training set, where the informa-
tion on comorbidities was available.
Pathway analysis
Pathway analysis was made using a ranked GSEA approach 
(Subramanian et al. 2005; Mootha et al. 2003), modified 
according to the specificity of our data. The metrics for gene 
ranking was calculated on the basis of the results of feature 
selection models, weighting in each Boolean feature both 
beta values and the number of bootstrap iterations where it 
was found significantly associated with severity/mildness 
(Supplementary Tables 3–6). All the Boolean features that 
were found significant in at least one of the models were 
included in the list. As the sign of beta depends on which 
allele is taken as reference (which is relative for common 
variants), we decided to use absolute beta values for all the 
features. To also weight the importance according to variant 
frequency, we used the F values from the IPGS score for the 
four categories (ultra-rare 5, rare 4, low frequency 2, com-
mon 1). Finally, we summed all the weights of each Boolean 
feature by gene. Briefly,
Pathway enrichment analysis was made using the GSEA-
preranked module (v. 7.2.4) of the Genepattern platform 
(Wang et al. 2010), on several pathway categories (BIO-
CARTA, KEGG, REACTOME, GOBP, HALLMARKS, 
C7 and C8), limiting the size of gene sets to the 10-300 




ABS(mean) × count × F.
showing similarity of significant pathways were built using 
the EnrichmentMap algorithm (Subramanian et al. 2005) 
in the Cytoscape suite (v. 3.8.2) (Merico et al. 2011; Shan-
non et al. 2003). Parameters used for network creations are: 
Jaccard Overlap Combined Index (k constant = 0.5), edge 
cutoff 0.05.
Website and data distribution
The coordination of international partners has been possible 
through the Host Genetics Initiative (HGI) (https:// www. 
covid 19hg. org/ proje cts/).
Results can be shared through the Gen-Covid website 
(https:// sites. google. com/ dbm. unisi. it/ gen- covid).
Code availability
Data analyses were performed using Python with the Scipy 
ecosystem (Virtanen et al. 2020), and the scikit-learn library 
(Pedregosa et al. 2011). Statistical association was done with 
the statsmodel Python library. The code is freely available 
at the github repository: https:// github. com/ gen- covid/ pmm.
Results
The post‑Mendelian paradigm for COVID‑19 
modelization for combining interpretability 
with predictivity based on ultra‑rare, rare, 
low‑frequency, and common variants
The aim of the present study was to develop an easily inter-
pretable model that could be used to predict the severity of 
COVID-19 from host genetic data. Patients were considered 
severe when hospitalized and receiving any form of respira-
tory support. The focus on this target variable is motivated 
by the practical importance of rapidly identifying which 
patients are more likely to require oxygen support, in an 
effort to prevent further complications. Interpretability has 
been a guiding principle in the definition of the machine-
learning model, as only a readily interpretable model can 
provide useful and reliable information for clinical practice 
while also contributing significantly to diagnostic, and thera-
peutic targeting. The high dimensionality of host genetic 
data poses a serious challenge to evident and reliable inter-
pretability. So far, the development of a robust predictive 
model able to make a direct association between single vari-
ants and disease severity grading based on an accurate analy-
sis of the vast number of host genetic variants compared to 
a much smaller number of individual patients has proven to 
be too complex and ultimately unreliable. To address the 
complexity with predictive reliability, an enriched gene-
level representation of host genetic data was modeled in a 
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machine-learning framework. The complexity of COVID-19 
immediately suggests that both common and rare variants 
are expected to contribute to the likelihood of developing 
a severe form of the disease. However, the contribution of 
common and rare variants to the severe phenotype is not 
expected to be the same. A single rare variant that impairs 
the protein function might cause a severe phenotype by itself 
after viral infection, while this is not so probable for a com-
mon polymorphism, which is likely to have a less marked 
effect on protein functionality. These observations led to the 
definition of a score, named IPGS, that includes data regard-
ing the variants at different frequencies:
In Eq. (1), n variables are used to indicate the number 
of input features of the predictive model that promote the 
severe outcome (superscript s) or that protect from a severe 
outcome (superscript m) and with genetic variants hav-
ing Minor Allele Frequency (MAF) ≥ 5% (common, sub-
script C), 1% < MAF ≤ 5% (low-frequency, subscript LF), 
0.1% < MAF ≤1% (rare, subscript R), and MAF < 0.1% 
(ultra-rare, subscript UR). The features promoting or pre-
venting severity were identified by an ensemble of logistic 
models, as described in the next section. The weighting fac-
tors FLF, R, and FUR were included to model the different 
penetrant effects of low-frequency, rare, and ultra-rare vari-
ants, compared to common variants. Thus, the 4 terms of 
Eq. (1) can be interpreted as the contributions of common, 
low-frequency, rare, and ultra-rare variants to a score that 
represents the genetic propensity of a patient to develop a 
severe form of COVID-19.
Feature selection and gene discovery
The definition of the single terms of the IPGS formula 
requires 4 separate steps (Fig. 1): (1) the definition of a 
severity phenotype adjusted by age and sex; (2) the conver-
sion of genetic variants into Boolean features that represent 
the presence of variants in different frequency ranges in 
each gene; (3) the selection of those features that are associ-
ated with disease severity; and (4) the optimization of the 
weighting factors appearing in Equation 1. These 4 steps 
were executed using data from a training set extracted from 
the GEN-COVID dataset (90% of the patients, n=1780, 
see Methods). The phenotype adjusted by age and sex 
was computed using an ordered logistic regression model, 
with the purpose of facilitating the extraction of features 
associated with the genetic basis of COVID-19 severity 
(Fig. 1B). The conversion of genetic variants into Boolean 
features led to the definition of 12 separate sets of input 









































“ultra-rare_autosomal dominant” (UR_AD) is designed to 
represent in a binary way an autosomal dominant hereditary 
model associated with variants with MAF lower than 0.1%, 
i.e. these Boolean features are equal to 1 for genes present-
ing at least one variant in this frequency range. Similarly, 
the set of input features “ultra-rare_autosomal recessive” 
(UR_AR) and “ultra-rare_X-linked” (UR_X) were designed 
to describe the autosomal recessive and X-linked models 
of inheritance of ultra-rare variants. Analogous principles 
were used for rare and low-frequency variants. In the case of 
common variants, the same 3 sets of Boolean features rep-
resenting the autosomal dominant, autosomal recessive, and 
X-linked models of inheritance were used. However, instead 
of simply defining the binary variables as “absence/presence 
of variants”, the absence/presence of variant combinations 
was tested (Fig. 1C).
The Boolean representation of the genetic variability 
described in the previous paragraph significantly reduces 
the dimensionality of the problem. However, the number 
of input features is still orders of magnitude higher than 
the number of patients that can be reasonably collected for 
training the model. To reduce the number of input features, 
a feature selection strategy based on logistic models with the 
validated Least Absolute Shrinkage and Selection Operator 
(LASSO) regularization was employed (Fig. 1D). The aim of 
LASSO regularization is to minimize (shrink) the number of 
coefficients of the model, consequently minimizing the num-
ber of input features used for predicting outcomes. Separate 
logistic models with LASSO regularization were trained for 
the 12 sets of Boolean features for predicting COVID-19 
severity, allowing us to identify the relevant features for each 
set. About 4% of the cumulative tested features were found 
to contribute to COVID-19 variability in severity (Fig. 1D). 
Twenty-six percent identity match between extracted genes 
and known viral susceptibility genes was found (Supple-
mentary Table 12). We further investigate extracted genes 
using the Human Gene Connectome (HGC). Interestingly, of 
the 4943 genes of our model that are mapped in HGC, 4401 
(89%) are biologically significantly connected (p < 0.05) 
and 2847 (57.6%) with a degree of 0 (overlap) or 1 (direct 
connection) with one of the genes of the three Core Lists 
(Supplementary Table 13).
Biological interpretability of extracted genetic 
features
Selected genes contributed by ultra-rare, rare, low-frequency 
variants, or/and common variants (Fig. 2A–D and Supple-
mentary Tables 3a–g). Specifically, 54% contributed by only 
one, 29% by two, 11% by three, and 6% by four types of 
variants. Around 25% of the genes were sex-specific. The 
latter group includes either genes located on the X chromo-
some, such as TLR7 and TLR8 in males, or genes regulated 
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in opposite directions by androgens and estrogens when 
contributing with less penetrant common variants, such as 
p.L412F in TLR3 and p.D603N in SELP gene (Fig. 2A–D).
Among the extracted ultra-rare variants there was a 
group of genes, such as TLR3, TLR7 and TICAM1, already 
shown to be directly involved in the Mendelian-like forms 
of COVID-19 (Fig. 2A and Supplementary Table 3a, b). 
Furthermore, another group of genes are natural candidates 
because of their function: these include the ACE2 shedding 
protein ADAM17, CFTR-related genes, genes involved in 
glycolipid metabolism, genes expressed by cells of the innate 
immune system, and genes involved in the coagulation 
pathway. Finally, a group of genes led by ACE2 (if affected 
by ultra-rare variants) confers protection from the severe 
disease. This group includes several genes whose mutations 
are responsible for auto-inflammatory disorders.
Among the rare variants extracted, we identified some 
genes as candidates for COVID-19 severity, including TLR5 
and SLC26A9 as well as other genes involved in the inflam-
matory response (Fig. 2B and Supplementary Table 4a, b).
Among the low-frequency variants extracted, we identi-
fied some genes associated with either severity or protection 
from severe COVID-19 that are linked to the CFTR path-
way (e.g., PSMA6) as well as specific genes involved in the 
immune response (e.g., NOD2) (Fig. 2C and Supplementary 
Table 5a, b).
The model was also able to identify a group of extracted 
common variants already shown to be linked to either severe 
Fig. 1  Feature selection and gene discovery. A Whole-exome 
sequencing (WES) data stored in the Genetic Data Repository of the 
GEN-COVID Multicenter Study (GCGDR) and coming from bio-
specimens of 1780 SARS-CoV-2 PCR-positive subjects of European 
ancestry of different severity were used as the training set. B Clini-
cal severity classification into severe and mild cases was performed 
by Ordered Logistic Regression (OLR) starting from the WHO grad-
ing and patient age classifications. C WES data were binarized into 
0 or 1 depending on the absence (0) or the presence (1) of variants 
(or the combination of two or more variants only for common poly-
morphisms) in each gene. D LASSO logistic regression feature selec-
tion methodology on multiple train-test splits of the cohort leads to 
the identification of the final set of features contributing to the clini-
cal variability of COVID-19 (E). From the initial 163,099 cumulative 
features (divided into 36,540 ultra-rare, 23,470 rare, 13,056 low fre-
quency and 90,033 common features) in 12 Boolean representations, 
the selected features contributing to COVID-19 clinical variability 
are 7249 and they are reported in the Supplementary Tables 3–6. The 
total number of genes contributing to COVID-19 clinical variability 




or mild COVID-19 (Fig. 2D and Supplementary Table 6a, 
b). Among them are the L412F TLR3 and D603N SELP 
polymorphisms, already reported to be associated with the 
severe disease (Croci et al. 2021; Fallerini et al. 2021b) and 
several coding polymorphisms in Linkage Disequilibrium 
(LD) with already reported genomic SNP, such as the ABO 
blood group, OAS1-3 genes, PPP1R15A gene and others 
(Elhabyan et al. 2020). In conclusion, considering their 
functions, genes involved in the immune and inflammatory 
responses, or those involved in the coagulation pathway and 
NK and T cell receptor, are to be considered natural candi-
dates for severe or mild COVID-19.
Integrated PolyGenic Score definition
The Boolean features selected by the LASSO logistic models 
were used to calculate ten variables in Eq. (1) (Fig. 3A, B). 
The corresponding weights (F variables) were defined by 
optimizing the separation between severe and mild cases as 
offered by the IPGS formula. The optimization was meas-
ured using the Silhouette coefficient, and the optimal values 
were computed using a grid-search approach over a prede-
fined grid (FLF ∈ [1, 4], FR ∈ [2, 8], and FUR ∈ [5, 100]).
This optimization returned values of 2, 4, and 5 for the 
low-frequency, rare, and ultra-rare variants, respectively 
(Fig. 3C, D).
Pathway analysis
To understand the biological mechanisms underlying the 
variability of disease, we performed a pathways analysis 
of the genes carrying variants discovered in the feature 
selection described above. The features obtained with this 
approach do not have the same predicted impact and are not 
discovered with the same confidence. Therefore, we decided 
to perform a rank-based pathway analysis, with genes with 
the highest impact and confidence ranking highest in the 
list, rather than a simple over-representation approach. We 
ranked all the genes that were found to be significantly 
associated with severity/mildness in at least one bootstrap 
repetition, based on a score that takes into account three 
parameters: average coefficient in the LASSO models select-
ing the feature, number of significant bootstrap results, and 
the F correction factor for the frequency category used in 
the IPGS (detailed in the Methods section below). For genes 
with more than one significant Boolean feature, we summed 
up the scores of each feature. Gene Set Enrichment Analysis 
(GSEA) was then performed using two separate ranked gene 
lists (Supplementary Table 7) for females and males, fol-
lowed by the generation of similarity networks using Enrich-
mentMap (Fig. 4A). The usage of rank-based search method 
allows to identify statistically significant pathways starting 
from extensive list genes, as each gene is associated with 
its specific importance. Although no pathways satisfied the 
0.25% FDR threshold normally required for standard GSEA 
analyses, the set of pathways considered significant using 
more relaxed thresholds on p values were shown to group in 
meaningful modules, providing useful information on patho-
genetic mechanisms and on the genes that could explain how 
they can be affected. The network of all the pathways signifi-
cantly enriched in both females and males ranked gene lists 
(p < 0.01, n = 25) is depicted in Fig. 4B, while the network 
of all the pathways enriched in either females or males with 
a more stringent p value (p < 0.005, n = 100) is shown in 
Fig. 4C. Detailed information on the names of the pathways 
and p values of enrichment is reported in Supplementary 
Figures 1 and 3. For the most representative pathways of 
each network, the heatmaps of the genes with their weights 
of association to disease variability are shown in Fig. 4D 
and Supplementary Figures 2 and 4, while gene lists and 
gene weights for all the significant pathways are reported in 
Supplementary Table 8.
COVID‑19 post‑Mendelian model predictivity
The functional interpretation of the variants identified by 
the feature selection approach, complemented by the strong 
link between the involved human biological pathways and 
COVID-19 pathogenicity, support the hypothesis that the 
IPGS score developed here may contribute significantly 
to predicting the severity of COVID-19. This hypothesis 
was tested using a logistic regression model that predicts 
COVID-19 severity based on age, sex and the IPGS (after 
percentile normalization). The training set is composed 
of 466 patients not included in the training set previously 
exploited for the IPGS feature engineering. The model’s 
performance was then tested using three independent 
cohort sets of European ancestry (Fig. 5A). The model 
exhibited an overall accuracy of 0.73, precision equal to 
0.78, with a sensitivity and specificity of 0.72 and 0.75, 
respectively. Noteworthy, all the aforementioned metrics 
are higher than the corresponding values obtained using 
a logistic model that adopted as input features only age 
and sex. The increase in performances of the model with 
IPGS suggests that this score indeed confers significant 
additional (genetic) information for predicting COVID-
19 severity compared to only age and sex. The increase 
of the performances is statistically significant (p value < 
0.05 for accuracy, precision, sensitivity, specificity) with 
respect to the distribution of performances for an ensemble 
of models where the IPGS feature has been randomized 
(Fig. 5C lower left). A third logistic regression model fit-
ted with IPGS alone, shows performances well above the 
random guess. Furthermore, the empirical probability den-
sity function of IPGS scores (Fig. 5C right) has been esti-
mated for the severe and non-severe patients of the cohort 
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including both training and testing sets. It is worth noting 
the shift on the right of the IPGS distribution for the severe 
patients, with significant p value (< 0.001) for the t test of 
mean difference. This difference between severe and non-
severe cases is preserved for the male and female cohorts 
when analyzed separately (p values < 0.001 and 0.024, 
respectively).
In line with the results obtained using the overall test set, 
the model including IPGS, age, and sex performed better than 
the model considering only sex and age as inputs, in each 
of the testing cohorts, separately (Fig. 5D). The increase in 
performance was systematically observed throughout all the 
cohorts: on average + 1.33% for accuracy, + 1% for precision, 
+ 1.33% for sensitivity, + 1.67% for specificity. Considering 
the difference in phenotype classification inherent to a com-
parison among various international cohorts, and the genetic 
variability among different European sub-populations, the 
consistent increase in performances observed for the model 
with IPGS demonstrates that this score provides a robust 
index for predicting COVID-19 severity. As a further test for 
the importance of the IPGS score for predicting COVID-19 
severity, the univariate logistic models were used on the over-
all set including both train and test cohorts to estimate the 
OR of severe COVID-19 for IPGS, age, and sex, separately. 
The test confirmed that severity was associated with IPGS, 
showing an OR of 2.32 (p < 0.001, 95% confidence interval 
[1.79, 3.01]) with age, measured in decades, and sex, having 
OR of 1.89 (p < 0.001, 95% confidence interval [1.79, 2.00]) 
and 2.99 (p < 0.001, 95% confidence interval [2.58, 3.46]) 
respectively (Fig. 5E). The multivariate logistic regression 
using sex, age, and IPGS together, provided similar results 
reported in Supplementary Table 9 confirming the goodness 
of the regressors’ OR. When adjusting for comorbidities, in 
the train cohort where the comorbidities were available, with a 
multivariable logistic model, OR of IPGS was 2.46 (p = 0.05, 
95% confidence interval [1.15, 5.25]) as shown in Supple-
mentary Table 10. This result further confirms that IPGS is a 
reliable predictor of COVID-19 clinical severity.
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Advantages of IPGS and clinical interpretability 
of connected features
We then wanted to compare the clinical outcome with the 
probability of severity obtained from three different models: 
IPGS alone, sex-age alone or combined model (represented 
as heatmap in Fig. 6). It appears evident that in a subset of 
patients, the 2 models based on sex-age alone and IPGS 
alone have a discordant prediction (left and right end of 
dendrogram in Fig. 6A). In these cases, IPGS appears to be 
a relevant predictor of severity (Fig. 6A). This is in accord-
ance with the above-presented logistic regression analysis 
(Fig. 5E) that shows IPGS having an OR of 2.32 for severity. 
Moreover, the list of features on which the IPGS score is 
built, represent a biological handle for pathophysiological 
mechanisms and possible personalized adjuvant treatments.
For example, three male patients, within two distinct age 
ranges (46–50, 51–55) (panels B, C and D) with severe out-
come (intubation and CPAP) are imperfectly represented by 
the sex-age model (probability of severity from 0.52 to 0.66) 
and better represented by the IPGS model (probability of 
severity from 0.91 to 0.95). The detected genetic variants 
that would allow to clinically consider putative personalized 
treatments in similar cases are: (1) TLR7 ultra-rare mutation 
indicating to consider possible adjuvant treatment with IFN 
gamma administration (Fallerini et al. 2021a); (2) homozy-
gosity 603Asn in SELP gene suggesting putative adjuvant 
treatment with anti-selectin P autoantibodies (e.g. Crizanli-
zumab) (Fallerini et al. 2021b) and (3) polyQ longer than 23 
in AR gene suggesting to consider possible adjuvant treat-
ment with testosterone (Baldassarri et al. 2021a).
In a female patient, within age range 31–35, the sex-age 
model showed a probability of severity of 0.17 (panel D) 
while the IPGS score was 336 corresponding to a probabil-
ity of severity of 0.95. The patient had no comorbidities 
except for hypothyroidism. She underwent steroid treat-
ment and CPAP ventilation. She was found to be carrier 
of ADAMTS13 ultra-rare mutation, being more suscepti-
ble to thrombosis (due to reduced capacity of cutting von 
Willebrand factor); she had indeed a high D-dimer value. 
Caplacizumab (an antibody anti-vWF) would be an option 
to consider as possible adjuvant treatment in the clinical 
management of similar cases.
Two male patients, within two distinct age ranges (81–85, 
86–90) (panel F and G) with a relatively mild respiratory 
outcome (hospitalised with low-flow oxygen therapy) pre-
sented an IPGS score of − 258 and − 141, respectively. 
Their severity probabilities calculated on sex-age (0.9 and 
0.94) do not mirror the relatively mild clinical outcome, 
which is instead better represented by the severity prob-
ability calculated in IPGS only (0.23 and 0.41). Those two 
patients presented ultra-rare variants in ACE2 gene, likely 
responsible for reduced viral load (Benetti et al. 2020b), and 
in AGTR2 gene, which reduced activity is known to prevent 
cystic fibrosis pulmonary manifestation (Darrah et al. 2019).
Fig. 2  Biological impact of ultra-rare, rare, low-frequency, and com-
mon features. Examples of ultra-rare (A), rare (B), low-frequency 
(C), and common (D) features are illustrated in panel A–D. The 
complete list of features is presented in Supplementary Tables  3–6. 
 = contributing to COVID-19 severity;  = contributing to 
COVID-19 mildness. Pink faces = contributing to females only; blue 
faces = contributing to males only; pink/blue faces = contribution 
in both sexes. In parentheses: AD = autosomal dominant inherit-
ance; AR = autosomal recessive inheritance; XL = X-linked reces-
sive inheritance. A Ultra-rare mutations in the RNA sensor TLR7, 
TLR3, and TICAM1 (encoding TRIF protein), already reported asso-
ciated with XL, AR and AD inheritance (Zhang et  al. 2020a; Van 
der Made et  al. 2020; Fallerini et  al. 2021a; Solanich et  al. 2021) 
impair interferon (IFNs) production in innate immune system cells. 
Mutations in TLR8, as well as of the signal transducer IRAK1 also 
impair interferon production. The specific location of TLR7/8 and 
IRAK1 (on the X chromosome) as well as X-inactivation escaping 
are responsible for opposite effects in males and females. Mutation 
in RNASEL impair the antiviral effect of the gene. In lung epithelial 
cells, ACE2 ultra-rare variants (on the X chromosome) exert protec-
tive effects (probably) due to lowering virus entrance, while ultra-rare 
variants in ADAM17 (might) reduce the shedding of ACE2 and induce 
a severe outcome. The same is true for CFTR and SCNN1A (encod-
ing ENaCA protein and involved in a CFTR-related physiological 
pathway), and the lipid transporter ABCA3 (Baldassarri et al. 2021b).
Mutations of ADAMTS13 in vessels reduce the cleavage of the multi-
meric von Willebrand Factor (VWF), leading to thrombosis; B) Rare 
variants of the estrogen regulated TLR5 are associated with severity 
in females. Rare variants of the CFTR-related SLC26A9 are associ-
ated with severity in both sexes. This ion transporter has three dis-
crete physiological modes: nCl(–)-HCO(3)(–) exchanger, Cl(–) chan-
nel, and Na(+)-anion cotransporter. Other examples of rare mutations 
associated with severity are the NK and T cell receptor FCRL6, IFN 
signal transducer IRAK2, and the actin depolymerization MICAL2; 
C low-frequency variants in another CFTR-related gene, SCNN1D 
(encoding for ENaCD protein) are associated with mildness, while 
rare variants in the following genes are associated with severity: 
cargo protein SPMA6, vesicle formation PEX1, inflammatory protein 
NOD2 (CARD15); D A number of coding polymorphisms, indicated 
with an asterisk, are in LD with genomic SNPs already associated 
with COVID-19 (The complete list is presented in Supplementary 
Table  11) (Severe Covid-19 GWAS Group (2020; Pairo-Castineira 
et al. 2020). In some cases, such as the case of SFTDP, the genomic 
SNP is the coding polymorphism itself. Of note are the genes of sur-
factant proteins associated with severe disease: SFTDP gene encod-
ing for SP-D protein and SFTPA1 gene encoding for SP-A protein; the 
signal transducer, PPP1R15A gene encoding for GADD34 protein. 
OAS1 and OAS3 related to RNA clearance of RNASEL (reported 
in panel A as having ultra-rare mutations; included here should also 
be the already reported TLR3412 (Croci et  al. 2021); the already 
reported SELP603 related to thrombosis (Fallerini et  al. 2021a). 
Note: OAS1 haplotype A = c.1039-1G>A (Wickenhagen et al. 2021), 
(p.(Gly162Ser)), (p.(Ala352Thr)), (p.(Arg361Thr)), (p.(Gly397Arg)), 
(p.(Thr358Profs*26)). OAS1 haplotype B = haplotype without the 





The most robust and traditional method for feature selection 
in complex disorders is Genome-wide association studies 
(GWASs). GWAS focuses on common variants only whose 
effects are small. The method is based on the comparison 
of about 700,000 genomic SNPs, mostly non-coding, in 
cases/controls. The coverage of coding SNPs is usually 
only through imputed data by Linkage Disequilibrium. The 
method needs ten/hundred of thousands subjects. The miss-
ing heritability of this method is rare variants. Until now, 
35 loci have been identified for COVID-19 severity (Severe 
Covid-19 GWAS Group 2020; Pairo-Castineira et al. 2020; 
COVID-19 Host Genetics Initiative et al. 2021). Another 
robust and traditional method is the Burden test. Burden 
focuses on coding rare variants. The method is based on 
aggregation on a gene level of the variants and comparison 
between case and control subjects and likewise GWAS needs 
ten/hundred of thousands subjects. The missing heritability 
of this method is common variants. Few genes have been 
identified (Kosmicki et al. 2021) (WES/WGSHGI Working 
Group https:// www. covid 19hg. org/ blog/ 2021- 09- 27- septe 
mber- 20- 2021- meeti ng/). None of the above methods until 
now has been able to reach predictivity of COVID-19 sever-
ity useful in clinical practice.
The new proposed model takes into account both com-
mon and rare variants and has the ability to extract signifi-
cant COVID-19 features (genes/variants) using a set of rela-
tively low numbers of subjects. Furthermore, employment 
of oligo-asymptomatic SARS-CoV-2-infected subjects as 
Fig. 3  Integrated PolyGenic Score Definition. A The model is based 
on the comparison of Boolean features of severity versus Boolean 
features of mildness. B Graphic representation of the IPGS for-
mula used for this model. C Principle for the calibration of different 
weighting factors based on the separation of severe and mild cases. D 
The obtained value for low-frequency, rare, and ultra-rare, being F = 1 
for common variants. Common variants are indicated as common 
haplotypes since they are intended as combinations of coding vari-




Fig. 4  Pathway enrichment analysis of the genes associated with 
disease severity/mildness. A Workflow of the analysis. Genes cor-
responding to Boolean features found to be associated at least once 
were ranked based on a composite score and subjected to Gene Set 
Enrichment Analysis. Two separate ranked gene lists for females 
(7317 genes, weight range 3 × 10–5-561) and males (7325 genes, 
weight range 7 × 10–5-452) were used. The list of significant path-
ways was analysed and presented as a similarity network: B Simi-
larity network of the pathways with a significant enrichment both in 
females and males (p < 0.01). The size of the circles is proportional to 
the pathway size. Significance above threshold is indicated by the red 
color. C Similarity network of the pathways with a significant enrich-
ment either in females (red left half of the circles) or males (red right 
half of the circles) (p < 0.005). D Heatmaps of the genes belonging 
to a selection of pathways of interest. The color gradient represents 
the weight of each gene, calculated and described in methods. Please 
note high ranking of TLR genes (TLR5, TLR8, TLR3 and TLR7) in 
the pathway of Response to Mechanical Stimulus, CFTR gene in Rec-
ognition for Clathrin-mediated endocytosis, RNASEL, TYK2, OAS1 
and OAS3 genes in Interferon alpha–beta signaling. Note also the 
presence of the relevant pathway of Exhaust vs Memory CD8 T cell 
Up that also includes TLR7 gene
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controls instead of general population is providing a sig-
nificant advantage in accuracy. Extracted genes were pri-
oritized by matching with known viral susceptibility genes 
and transcriptomic data (Supplementary Table 12). Iden-
tity match was found for more than 25% of genes, even if 
the transcriptomic list is far to be representative of whole 
transcript alteration in the several tissues/organs involved in 
COVID-19 since most data comes from 2 tissues only (lung 
and swab). More than 55% of genes have a direct connec-
tion (degree 0 and 1 in HGC) with viral susceptibility genes, 
including those from GWAS loci and the genes in eQTL 
with them by GTEX analysis (Supplementary Table 13). 
Finally, up to 89% of genes are biologically significantly 
connected (p < 0.05) with the list above, supporting the vali-
dation of extracted genes.
Fig. 5  Model predictivity. A The post-Mendelian model was trained 
using a sample of 466 patients from the GEN-COVID cohort n.2 
and Swedish cohort (having cases only) and tested with three addi-
tional European cohorts from UK, Germany and Canada. B A logis-
tic regression model was used for severity prediction. Severity was 
defined mainly on the basis of hospitalization versus not hospitaliza-
tion. Hospitalized cases without respiratory support were included in 
controls. TN = true negative; TP =  true positive; FN =  false negative; 
FP =  false positive. C When the IPGS is added to age and gender as 
a regressor, the performances of the model increase: accuracy + 1%, 
precision + 1%, sensitivity + 2%, specificity + 1%. These increases are 
statistically significant (p value < 0.05 for accuracy, precision, sensi-
tivity and specificity) with respect to the null distribution obtained 
by randomizing the IPGS. The performances of the model built with 
IPGS alone are all above the random guess. In addition, on the right, 
we reported the distributions of the IPGS for severe and non-severe 
patients. D In the three tested cohorts, when the IPGS is added to age 
and sex as a regressor, all the performances increase: the accuracy up 
to + 2%, the precision up to + 1%, the sensitivity up to + 3%, and the 
specificity up to + 2%. We conclude that IPGS is able to improve pre-
diction of clinical outcome in addition to the well-established power-
ful factors of age and sex. E The univariate logistic regression mod-
els fitted on the cohort including both train and test, confirmed that 
the IPGS is associated with severity with an odds-ratio (OR) of 2.32, 




The importance of combination of rare and low-frequency 
variants has already been demonstrated to contribute to 
the prediction of susceptibility in other complex disor-
ders (Marouli et al. 2017; International Multiple Sclerosis 
Genetics Consortium 2018). Here, we further expand this 
approach while demonstrating that ultra-rare, rare, low 
frequency, as well as common variants contribute to the 
likelihood of developing a severe form of COVID-19. Fur-
thermore, we included in our analyses a calibration of the 
relative weight of the variants vis-a-vis their impact on dis-
ease severity: a single ultra-rare variant might well by itself 
cause a severe phenotype of COVID-19, while this is less 
probable for a common polymorphism, one that is likely to 
have a markedly less direct effect on protein functionality. 
We performed a first modelization of COVID-19 genetics 
using both rare and common variants (Picchiotti et al. 2021). 
Since feature selection methodologies are generally sensitive 
to allele frequency, the extraction was performed separately 
Fig. 6  Clinically interpretability of IPGS. Panel A shows the GEN-
COVID cohort dendrogram and heatmaps of the probabilities of 
severity based on the 3 different models: sex-age alone, IPGS alone 
and combined model. In the extreme ends of dendrogram (left and 
right) the probability of severity based on sex-age alone and IPGS 
alone is highly discordant (different colors). Selected examples cor-
responding to the arrows are illustrated in panels B-G. In each panel 
IPGS score, probabilities of severity and key features useful for bed-
side clinical management are shown. B) Male patient, in the 46–50 
age range, treated with CPAP ventilation, tocilizumab, enoxaparin, 
hydroxychloroquine and lopinavir/ritonavir; no comorbidities except 
for asthma have been reported. The patient presented a rare TLR7 
mutation that leads to an impaired production of interferon gamma 
(Made et al. 2020). C) Male patient, in the 51–55 age range, treated 
with invasive mechanical ventilation, steroids and enoxaparin. He 
had among comorbidities obesity, anxiety, hypertension and cer-
ebral ischemia. He was found to be homozygous for the SELP rs6127 
(p.Asp603Asn). Homozygosity of Asparagine in position 603 of 
Selectin P makes this endothelial protein more prone to clot forma-
tion and male patients more prone to COVID-19 thrombosis (Croci 
et  al. 2021). Hence, the rationale for considering as putative adju-
vant therapy in the management of similar cases the anti-Selectin 
P antibodies, a drug already approved for vascular events of sickle 
cell anemia. D) Male patient, in the 51–55 age range, treated with 
CPAP ventilation, tocilizumab, steroids, enoxaparin, hydroxychlo-
roquine and lopinavir/ritonavir; no comorbidities except for diabe-
tes. He was found to have the androgen receptor polyQ repeats > 23. 
The regular function of the androgen receptor is correlated with a 
beneficial immunomodulatory effect in those male patients in whom 
the increase in testosterone levels may overcome the receptor resist-
ance. The rationale is to consider giving testosterone to those male 
subjects who cannot, on their own, raise the levels enough to over-
come the receptor resistance due to poly-glutamine stretch longer 
than 23 repeats (Daga et  al. 2021). E) Female patient, in the 31–35 
age range, treated with CPAP ventilation and steroids, enoxaparin and 
azithromycin; no comorbidities except for hypothyroidism. She was 
a carrier of an ultra-rare mutation in ADAMTS13. Impaired function 
of ADAMTS13 leads to reduced cleavage of von Willebrand fac-
tor (vWF) and enhanced clot formation. The effect is enhanced in 
females and responsible for SARS-CoV-2 related thrombosis. Anti-
vWF immunoglobulins would be a putative therapeutic option to 
consider in similar cases. F-G) examples of low IPGS and related key 
features. F) Male patient, in the 81–85 age range, treated with low-
flow oxygen. No information regarding pharmacological therapy 
during hospitalization is present. Among comorbidities: diabetes 
mellitus, congestive heart failure and bowel cancer and steroids. He 
presented an ultra-rare mutation in ACE2. G) Male patient, in the 
86–90 age range, treated with low-flow oxygen, steroid, enoxaparin 
and ceftriaxone plus azithromycin. Among his comorbidities: colon 
diverticulosis with constipation?, benign prostatic hyperplasia?, anx-
ious-depressive syndrome, sideropenic anemia. He was a carrier of an 
ultra-rare mutation in AGTR2 
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for rare (MAF < 1/100) and common (MAF > 1/100) vari-
ants. However, the methodology revealed the insight that 
low-frequency variants (MAF from 1 to 5%) were disadvan-
taged if selected together with common ones. Furthermore, 
for extracting Mendelian-like genes a threshold of MAF 
< 0.1% (ultra-rare variants) appeared more effective than 
MAF < 1% and all mutations in the TLR7 gene that proved 
to have loss of function had indeed MAF < 1/1000 (Fallerini 
et al. 2021a). The model we arrived at, now considers sepa-
rately ultra-rare, rare, low-frequency, and common variants.
Similar to the classical PRS (Polygenic Risk Score), the 
proposed IPGS (Integrated PolyGenic Score) may prove 
reliable for assessing the probability of severe COVID-19 
following infection by SARS-CoV-2 (Mars et al. 2020). 
While PRS is based on common polymorphisms found at the 
genomic level with the majority of loci potentially confer-
ring risk being not easily interpretable due to the uncertainty 
of linked genes, IPGS allows immediate biological interpre-
tation because it only includes coding variants. Furthermore, 
as opposed to PRS, IPGS relies on both polymorphisms and 
rare variants is capable of differentially weighting features in 
an indirectly proportional way in respect to frequency, and 
therefore, to protein impact. Each patient indeed is assigned 
both a number and the list of her/his common and low-fre-
quency polymorphisms relevant to COVID-19 supported 
by medically actionable information and of rare and ultra-
rare variants conferring either risk of severity or protection 
from severe disease. Drawing on the entire picture presented 
through IPGS analysis, personalized adjuvant therapy could 
be envisaged. At the time of writing, a platform trial based 
on genetic markers is being discussed with the Italian Medi-
cines Agency (EudraCT Number: 2021-002817-32).
Within 25 reported genomic SNPs demonstrably related 
to COVID-19 susceptibility/severity, 5 were reported to be 
in LD with coding variants (COVID-19 Host Genetics Initia-
tive et al. 2021; Covid19hg.org 2021). The model presented 
here might provide useful information for uncovering the 
identity of the gene/coding variants responsible for COVID-
19 susceptibility/severity linked to these genomic SNPs 
(Fig. 2D). For example, on chromosome 12, the genes map-
ping to the locus tagged by rs10774671 (COVID-19 Host 
Genetics Initiative et al. 2021) are both OAS1 and OAS3. In 
OAS3, the coding variant is an Arginine to Lysine substitu-
tion (rs1859330) in high LD (0.8) with the tag SNP. This 
polymorphism was already associated with viral infection 
(Tan et al. 2017) based on the presence of Lysine having 
been shown to lead to a decreased INF-γ production. In 
OAS1, the haplotype (including 4 missense variants: G162S, 
A352T, R361T, and G397R), the splicing variant 1039-G>A 
(the reported genomic polymorphism itself), and the trun-
cating mutation T359fs*26 are associated with severity and 
predicted to impair OAS1 function. Both OAS1 and OAS3 
induce RNASEL, which in turn exerts antiviral activity. 
Further support for the role of the OAS/RNASEL axis is 
indicated by the presence of ultra-rare recessive variants.
This innovative approach allowed us to better select genes 
located on the X chromosome related to COVID-19 that 
affect males and females in opposite ways (Fig. 2A and Sup-
plementary Tables 3 and 6). Interestingly, many of these 
genes were previously confirmed or hypothesized to escape 
the X chromosome inactivation. With respect to these genes, 
females produce twice the levels of protein in comparison 
with males. Mutations in hemizygous state in males and het-
erozygous state in females appear silent until SARS-CoV-2 
infection occurs. For example, TLR7 and TLR8 are selected 
for ultra-rare and associated with severity in males and with 
protection from severe disease in heterozygous females. 
We know that the activation of TLR7/8 induces the produc-
tion of type 1 and type 2 IFN as well as pro-inflammatory 
cytokines, where the production defect in hemizygous males 
leads to severe COVID-19. However, an excess of the sensor 
can also lead to damage from hyperinflammation. Therefore, 
the condition of carrier females is the more favorable state 
and has in fact been associated with mild COVID-19 (Sub-
ramanian et al. 2006).
Pathway analysis pointed to the relevance of obvious 
actors in COVID-19 pathology, such as immune cells and 
interferon signaling, but also to the important role of spe-
cific organs (brain, digestive tract, kidney, reproductive sys-
tem) and functions (metabolism of lipids and steroids). The 
pathways identified through GSEA analyses reflected the 
multi-organ nature of the disease. In addition, our analyses 
reveal new candidate determinants of disease variability. The 
four pathways linked to cilium motility suggest a role for 
ciliated cells of the respiratory tract (and possibly others) in 
antiviral defense. The functionality of the clathrin-mediated 
endocytosis pathway may likely affect viral entry (Bayati 
et al. 2021). Likewise, endoplasmic reticulum associated 
protein degradation (ERAD), which is linked to autophagy 
and SARS-CoV-2 life-cycle (Reggiori et al. 2010), may also 
be relevant. Other pathways with a less obvious but poten-
tially interesting role in the disease include cell adhesion and 
mechanical stimulus signaling.
The strong link between the involved human biological 
pathways and COVID-19 pathogenicity support the hypoth-
esis that the proposed IPGS equation may contribute sig-
nificantly to predicting the disease severity of COVID-19. 
Indeed, an overall significant increase of performance was 
obtained in comparison with the model based on solely on 
age and sex. Furthermore, the IPGS is significantly associ-
ated with severity, showing an OR of 2.46 after adjustment 
for age, sex, and comorbidities. This indicates that IPGS is 
a novel prognostic factor that should be considered in the 
management of COVID-19 patients.
Modelling precisely the role of the entire range of host 
genomics affecting disease susceptibility and severity in 
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COVID-19 is critical to obtaining a complete biological 
understanding of the aetiology and pathogenicity of COVID-
19 as well as other severe complex diseases. The applica-
tion of IPGS based on Machine Learning principles within 
a post-Mendelian model allows us to more precisely identify 
the gene variants at play in COVID-19 as well as their spe-
cific roles, individually and in combination. This deep dive 
into the genetic architecture that allows for, contributes to, 
or even helps prevent diseases while increasing or decreas-
ing their impact is critical for, and directly translatable into, 
(personalized) medicines development as well as prevention 
and treatment protocols. An integrated modelling of genetic 
variants based on a limited patient cohort, even limited in its 
geographical spread, may be sufficient for the development 
of diagnosis, and therapeutics across a wider range of popu-
lations. The advantage of this IPGS post-Mendelian model is 
that it learns and continues to learn as well as being a model 
from which we can obtain insights on the fundamental archi-
tecture of human genomics when confronted with severe and 
complex diseases.
Supplementary Information The online version contains supplemen-
tary material available at https:// doi. org/ 10. 1007/ s00439- 021- 02397-7.
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